nach oben

Erschienen in:

25.03.2019 | Apoplex | FORTBILDUNG . ÜBERSICHT

Jetzt muss es schnell gehen

Der akute Schlaganfall

verfasst von: Dr. med. Clemens Küpper, Dr. med. Johanna Heinrich, Katharina Müller, Dr. med. Katharina Feil, PD Dr. med. Lars Kellert

Erschienen in: MMW - Fortschritte der Medizin | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

„Time is brain“ — beim akuten Schlaganfall darf man nicht zögern. Betroffene müssen möglichst rasch einer systemischen Thrombolyse oder mechanischen Rekanalisation unterzogen werden. Beide Verfahren haben die Schlaganfallversorgung revolutioniert. Erfahren Sie hier auch alles zu den neuesten Entwicklungen im Bereich der Sekundärprophylaxe.

Feigin VL et al. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. Neuroepidemiology. 2015;45:161–76CrossRef

GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Causes of Death, Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–1544CrossRef

Centers for Disease and Prevention. Prevalence and most common causes of disability among adults — United States, 2005. MMWR Morb Mortal Wkly Rep. 2009;58:421–6

Adamson J, Beswick A, Ebrahim S. Is stroke the most common cause of disability? J Stroke Cerebrovasc Dis. 2004;13:171–7CrossRef

Heuschmann PU et al. Schlaganfallhäufigkeit und Versorgung von Schlaganfallpatienten in Deutschland. Akt Neurol. 2010;37:333–40CrossRef

Lozano, R., et al., Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012. 380:2095–128CrossRef

Adams HP Jr. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41CrossRef

Hart RG et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014; 13:429–38CrossRef

Nor AM et al. Agreement between ambulance paramedic- and physician-recorded neurological signs with Face Arm Speech Test (FAST) in acute stroke patients. Stroke. 2004;35:1355–9CrossRef

10.

Harbison J et al. Diagnostic accuracy of stroke referrals from primary care, emergency room physicians, and ambulance staff using the face arm speech test. Stroke. 2003; 34:71–6CrossRef

11.

Brott T et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864–70CrossRef

12.

van Swieten JC et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–7CrossRef

13.

Barber, P.A., et al., Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet, 2000. 355(9216):1670–4CrossRef

14.

Puetz V et al. Extent of hypoattenuation on CT angiography source images in basilar artery occlusion: prognostic value in the Basilar Artery International Cooperation Study. Stroke. 2011;42:3454–9CrossRef

15.

Puetz V et al. Extent of hypoattenuation on CT angiography source images predicts functional outcome in patients with basilar artery occlusion. Stroke. 2008;39:2485–90CrossRef

16.

Tei H et al. Posterior circulation ASPECTS on diffusion-weighted MRI can be a powerful marker for predicting functional outcome. J Neurol. 2010;257:767–73CrossRef

17.

Grau AJ et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke. 2001;32:2559–66CrossRef

18.

Hacke W et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29CrossRef

19.

Wahlgren N et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372:1303–9CrossRef

20.

Group ISTC et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379:2352–63CrossRef

21.

Ringleb P et al. Akuttherapie des ischämischen Schlaganfalls — Rekanalisierende Therapie (Ergänzung 2015). 2015 01.12.2017]; Available from: https://www.dgn.org/leitlinien/3198-030-140-rekanalisierende-therapie-ergaenzung-akuttherapie-schlaganfall.

22.

Thomalla G et al. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med. 2018;379:611–22CrossRef

23.

Fiehler J, Gerloff C. Mechanical Thrombectomy in Stroke. Dtsch Arztebl Int. 2015;112:830–6PubMedPubMedCentral

24.

Berkhemer OA et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11–20CrossRef

25.

Goyal M et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019–30CrossRef

26.

Campbell BC et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009–18CrossRef

27.

Saver JL et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372:2285–95CrossRef

28.

Jovin TG et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296–306CrossRef

29.

Goyal M et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723–31CrossRef

30.

Nogueira RG et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018; 378:11–21CrossRef

31.

Kumar G, Shahripour RB, Alexandrov AV. Recanalization of acute basilar artery occlusion improves outcomes: a meta-analysis. J Neurointerv Surg. 2015;7:868–74CrossRef

32.

Langhorne P et al. Do stroke units save lives? Lancet. 1993;342:395–8CrossRef

33.

Johnson ES et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med. 1999;159:1248–53CrossRef

34.

Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348:1329–39CrossRef

35.

Johnston SC et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369:283–92CrossRef

36.

Johnston SC et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018;379:215–25CrossRef

37.

Rothwell PM et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018; 392:387–99CrossRef

38.

Hart RG, Pearce LA, Aguilarand MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007:146:857–67CrossRef

39.

Endres M, Diener H, Röther J. S3 Leitlinie Sekundärprophylaxe des ischämischen Insults. Stand 31.1.2015, Registernummer 030 - 133, www.awmf.org/leitlinien/detail/ll/030-133.html. 30.03.2017]; Available from: https://www.dgn.org/leitlinien/3024-ll-23-ll-sekundaerprophylaxe-ischaemischer-schlaganfall-und-transitorische-ischaemische-attacke#Downloads.

40.

Vergouwen MD et al. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke; 2008;39:497–502CrossRef

41.

Catapano AL et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37:2999–3058CrossRef

42.

Zonneveld TP et al. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2018;7:CD007858PubMed

43.

Barnett HJ et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. 1998;339:1415–25CrossRef

44.

Furlan AJ et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991–9CrossRef

45.

Meier B et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368:1083–91CrossRef

46.

Carroll JD et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092–100CrossRef

47.

Mas JL et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017;377:1011–21CrossRef

48.

Sondergaard L et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017;377:1033–42CrossRef

49.

Saver JL et al. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017;377:1022–32CrossRef

50.

Lee PH et al. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. J Am Coll Cardiol. 2018;71:2335–42CrossRef

51.

Diener HC et al. Kryptogener Schlaganfall und offenes Foramen ovale, S2e-Leitlinie, 2018; in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Online: www.dgn.org/leitlinien 21.10.2018]; Available from: https://www.dgn.org/leitlinien/3637-ll-030-142-kryptogener-schlaganfall-und-offenes-foramen-ovale-2018

Titel: Jetzt muss es schnell gehen
Der akute Schlaganfall
verfasst von: Dr. med. Clemens Küpper
Dr. med. Johanna Heinrich
Katharina Müller
Dr. med. Katharina Feil
PD Dr. med. Lars Kellert
Publikationsdatum: 25.03.2019
Verlag: Springer Medizin
Schlagwort: Apoplex
Erschienen in: MMW - Fortschritte der Medizin / Ausgabe Sonderheft 1/2019
Print ISSN: 1438-3276
Elektronische ISSN: 1613-3560
DOI: https://doi.org/10.1007/s15006-019-0008-8

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2019

CME: Asthma bronchiale

Sexuelle Nebeneffekte der Medikation vermeiden

Die Krankheit an der Iris abgelesen — ganz wissenschaftlich

Neuer NNRTI zugelassen

Zahnlosigkeit begünstigt Hypertonie

„Phytopharmaka haben auch bei Influenza große Bedeutung“